Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrea Schilling Redlich"'
Publikováno v:
Revista Chilena de Obstetricia y Ginecología, Vol 76, Iss 5, Pp 344-353 (2011)
Objetivo: Demostrar la influencia sobre las molestias emocionales y físicas (beneficios no anticonceptivos) experimentadas durante el primer año de uso de un anticonceptivo oral combinado (AOC) que contiene 0,02 mg de etinilestradiol (EE) y 2 mg de
Externí odkaz:
https://doaj.org/article/49a2c65d260d4c20a197db766a2801c7
Autor:
Iona Cosgarea, Carlos Vergara-Sanchez, Mayumi Toyama, Andrea Schilling-Redlich, Olivier F. Clerc, Rami Nassir, Carolina Ogawa-Matsubayashi, Ludmilla Candido-Santos, Walla Abdalla-Mohamed, Jennifer C Eaton, Maryam M Aldosari, Renata Meneguetti, Sílvia Corradi Faria de Medeiros, Alma Sanchez-Jimenez, Gelanys Castro-Tejada, Ana Cecilia Scultori S Teles, Johnny Camargo, Felipe F. Gonzalez, Oriol Baptiste-Sainvil, David Hernandez-Herrero, Marianne Nakai, Angela Dominguez-Rodriguez, Gustavo A Grandez-Castillo, Rafael Augusto Paes-Lima-Rocha, Tamar DuBois, Judith A Vasquez, Yuri Takehara-Chemale, Ahmed Elyas, Eduardo Tsuyoshi Yamaguchi, Amarilis Then-Paulino, Weiguo Yao
Publikováno v:
Principles and Practice of Clinical Research Journal. 6:15-22
Introduction: Heart failure affects numerous patients and carries a 50% 5-year mortality rate from the time of diagnosis. Current treatment is based on medication, device therapy and revascularization to reduce morbidity and mortality. However, stem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be0f35c34d830d3be1b38b6aa7983191
https://doi.org/10.21801/ppcrj.2020.61.4
https://doi.org/10.21801/ppcrj.2020.61.4
Autor:
Roslye Berrios, Cristian Gutierrez-Vera, Bárbara M. Schultz, Patricio Andres Astudillo Paredes, GUILLERMO HOPPE ELSHOLZ, Luisa Fernanda Duarte Peñaloza, Andrea Schilling Redlich, Jorge Soto, Richard Garcia, Felipe Melo-Gonzalez, Fernando Valiente-Echeverria
BackgroundMultiple vaccines against SARS-CoV-2 have been evaluated in clinical trials, but very few include the pediatric population. The inactivated vaccine CoronaVac® has shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d3c1de18a9519ff852cfacd1ca94e9
https://doi.org/10.1101/2022.02.15.22270973
https://doi.org/10.1101/2022.02.15.22270973
BackgroundSeveral vaccines have been developed to control the COVID-19 pandemic. CoronaVac® (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe COVID-19 cases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::083fbfdcdf86483a63b1856524acd404
https://doi.org/10.1101/2022.02.07.22270215
https://doi.org/10.1101/2022.02.07.22270215